Development and validation of an isoform-independent monoclonal antibody–based ELISA for measurement of lipoprotein(a)

Marcovina, Santica M.; Navabi, Nazanin; Allen, Serena; Gonen, Ayelet; Witztum, Joseph L.; Tsimikas, Sotirios

doi:10.1016/j.jlr.2022.100239

Cited by 17 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accordingly, kits that aim to quantify the mass concentration of Lp(a) are more prone to variation compared to molarity-measuring tests, leading to diverging values of different mass-targeting kits, even within the same population with a standard Lp(a) molar concentration [ 60 , 61 ]. Despite this issue and the apo(a)-insensitive quantifying methods, [ 61 , 62 ] commercial kits measuring Lp(a) in mg/dL instead of estimating its molarity in nmol/L are still amply encountered in practice and the literature [ 63 , 64 ]. Moreover, converting the mass concentration of Lp(a) to its molar equivalent (mg/dL to nmol/L) cannot produce accurate results, although attempts have been made and a rough 2–2.5× conversion factor has been proposed [ 65 ].…”

Section: Measurement Of Plasma Lp(a) Concentration and Standardizationmentioning

confidence: 99%

Lipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment

et al. 2023

View full text Add to dashboard Cite

Lipoprotein(a) (Lp(a)) is a low-density lipoprotein (LDL) cholesterol-like particle bound to apolipoprotein(a). Increased Lp(a) levels are an independent, heritable causal risk factor for atherosclerotic cardiovascular disease (ASCVD) as they are largely determined by variations in the Lp(a) gene (LPA) locus encoding apo(a). Lp(a) is the preferential lipoprotein carrier for oxidized phospholipids (OxPL), and its role adversely affects vascular inflammation, atherosclerotic lesions, endothelial function and thrombogenicity, which pathophysiologically leads to cardiovascular (CV) events. Despite this crucial role of Lp(a), its measurement lacks a globally unified method, and, between different laboratories, results need standardization. Standard antilipidemic therapies, such as statins, fibrates and ezetimibe, have a mediocre effect on Lp(a) levels, although it is not yet clear whether such treatments can affect CV events and prognosis. This narrative review aims to summarize knowledge regarding the mechanisms mediating the effect of Lp(a) on inflammation, atherosclerosis and thrombosis and discuss current diagnostic and therapeutic potentials.

show abstract

Section: Measurement Of Plasma Lp(a) Concentration and Standardizationmentioning

confidence: 99%

Lipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment

et al. 2023

View full text Add to dashboard Cite

show abstract

“…This causes poorly harmonized results and in a high number of out-layers by comparing data obtained with different assays. There are currently two reference methods propagated based on LC-MS methods [38,39]. Hopefully, these two research groups will provide soon some new reference material that should be the basis for standardization of commercial assays in order to harmonize the results from different clinical laboratories.…”

Section: What Needs To Be Done To Harmonize Lipoprotein(a) Measuremen...mentioning

confidence: 99%

The 10 essential questions regarding lipoprotein(a)

Kostner,

Kostner

2023

Current Opinion in Clinical Nutrition &Amp; Metabolic Care

View full text Add to dashboard Cite

Purpose of review Lp(a) is one of the most atherogenic lipoproteins, and significant progress has been made to understand its pathophysiology over the last 20 years. There are now selective therapies in late-stage clinical trials to lower Lp(a). Yet there are many outstanding questions about Lp(a). This review outlines 10 of the most burning questions and tries to answer some of them. Recent findings Antisense oligonucleotide (ASO) treatment is currently the most advanced therapy to lower plasma Lp(a) by 60–80%. There are, however, also two small molecule medications in early stage of development with similar efficacy. Summary This review aims to answer important preclinical and clinical questions about the metabolism and physiological role of Lp(a) and also outlines possible therapeutic approaches with nutraceuticals, currently available lipid-lowering therapies and new medications. In addition, ways are illustrated to use Lp(a) as a marker to better predict cardiovascular risk.

show abstract

“…Testing for repeatability, linearity, and range are additional criteria that can indicate EDT performance [21], [22]. The repeatability of measurements is expressed as per cent relative standard deviation (%RSD), as presented in Table 4.…”

Section: The Performance Of Edge Detection Techniquementioning

confidence: 99%

Edge Detection Technique for Simultaneous Measurement of Total Suspended Solids and Turbidity

Hakiki

2023

GEOMATE

View full text Add to dashboard Cite

APHA Standard methods 2130B and 2540D have proven valid and reliable methods to determine turbidity and total suspended solids (TSS). However, both methods have drawbacks and limitations. Carcinogenicity of formazin, inconsistency in preparation, and interference are the primary concerns in turbidity measurement. Equipment complexity, working steps, and measurement time are primary concerns in TSS measurement. The edge detection technique (EDT) is an alternative to overcome the drawbacks and limitations. This research aims to conduct the performance test of the proposed method using pro-analytical grade kaolin (Sigma-Aldrich K7375), which has non-toxic properties compared to the formazin standard. Natural water samples from three different sampling locations became another subject in the EDT-based measurement method performance test. Steps included are elemental characterization with SEM-EDS-JEOL-JSM6510LA and particle size analysis with zeta sizer Horiba SZ-100. Turbidity measurement with Eutech TN100 and the TSS measurement with the gravimetric approach. Counted particle (CP) measurement through the EDT compared with the standard measurement. It showed that kaolin characteristics are closer to the natural suspension indicated by the more identical elemental compositions than the formazin elemental characteristics. Another result showed a correlation between kaolin concentration (KC), turbidity level, TSS concentration, and the counted particle is > 0.9. The proposed approach showed promising results indicated by the % Relative Standard Deviation < 20% for KC 0.5-20 mg/L and < 40% for KC 40-100 mg/L, in the linear range of 0.5-100 mg/L. Using a sample cell with a flat surface may improve the performance of the proposed approach. It is thus possible to reduce the reflection of light, which is a noise source in the measurement result.

show abstract

Development and validation of an isoform-independent monoclonal antibody–based ELISA for measurement of lipoprotein(a)

Cited by 17 publications

References 29 publications

Lipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment

Lipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment

The 10 essential questions regarding lipoprotein(a)

Edge Detection Technique for Simultaneous Measurement of Total Suspended Solids and Turbidity

Contact Info

Product

Resources

About